[HTML][HTML] Treatment options for COVID-19: The reality and challenges

SS Jean, PI Lee, PR Hsueh - Journal of microbiology, immunology and …, 2020 - Elsevier
An outbreak related to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
was first reported in Wuhan, China in December 2019. An extremely high potential for …

A review of the preclinical and clinical efficacy of remdesivir, hydroxychloroquine, and lopinavir-ritonavir treatments against COVID-19

D Maciorowski, SZE Idrissi, Y Gupta… - … the Science of Drug …, 2020 - journals.sagepub.com
In December of 2019, an outbreak of a novel coronavirus flared in Wuhan, the capital city of
the Hubei Province, China. The pathogen has been identified as a novel enveloped RNA …

COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2)

Y Song, M Zhang, L Yin, K Wang, Y Zhou… - International journal of …, 2020 - Elsevier
Currently, there is no approved therapy for coronavirus disease 2019 (COVID-19). The
World Health Organization (WHO) therefore endorses supportive care only. However …

Effectiveness of remdesivir, lopinavir/ritonavir, and favipiravir for COVID-19 treatment: a systematic review

WF Qomara, DN Primanissa, SH Amalia… - … journal of general …, 2021 - Taylor & Francis
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel
strain that causes acute respiratory illnesses known as coronavirus disease 2019 (COVID …

Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence

Y Cao, Q Deng, S Dai - Travel medicine and infectious disease, 2020 - Elsevier
The novel coronavirus infection that initially found at the end of 2019 has attracted great
attention. So far, the number of infectious cases has increased globally to more than 100 …

[HTML][HTML] Clinical efficacy of antiviral agents against coronavirus disease 2019: a systematic review of randomized controlled trials

CC Lai, CM Chao, PR Hsueh - Journal of Microbiology, Immunology and …, 2021 - Elsevier
Despite aggressive efforts on containment measures for the coronavirus disease 2019
(COVID-19) pandemic around the world, severe acute respiratory syndrome coronavirus 2 …

[HTML][HTML] Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2

K Uzunova, E Filipova, V Pavlova, T Vekov - Biomedicine & …, 2020 - Elsevier
Abstract Coronavirus disease 2019 (COVID-19) is a kind of viral pneumonia with an unusual
outbreak in Wuhan, China, which is caused by severe acute respiratory syndrome …

Tackling COVID‐19 using remdesivir and favipiravir as therapeutic options

O Sreekanth Reddy, WF Lai - ChemBioChem, 2021 - Wiley Online Library
The human world is currently influenced largely by the outbreak of pandemic COVID‐19. At
this moment, most researchers focus on developing treatment strategies and measures to …

[HTML][HTML] Medical management of COVID-19: evidence and experience

S Bose, S Adapa, NR Aeddula, S Roy… - Journal of clinical …, 2020 - ncbi.nlm.nih.gov
Coronavirus disease 2019 is caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), and this infectious disease is termed COVID-19 in short. On a global scale …

Arguments in favour of remdesivir for treating SARS-CoV-2 infections

WC Ko, JM Rolain, NY Lee, PL Chen, CT Huang… - International journal of …, 2020 - Elsevier
Since the end of 2019, an increasing number of cases of pneumonia were reported in
Wuhan, followed by other cities and provinces in China and many other countries …